Saxenda: Underlying Mechanisms and Clinical Outcomes

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

NCT03158805 ·Status: COMPLETED ·Phase: PHASE2

Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects

NCT03041792 ·Status: COMPLETED ·Phase: PHASE1

Saxenda in Obesity Services (STRIVE Study)

NCT03036800 ·Status: COMPLETED ·Phase: PHASE4

The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients

NCT04605861 ·Status: COMPLETED ·Phase: PHASE3

To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

NCT03795701 ·Status: COMPLETED ·Phase: NA

Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.

NCT05285397 ·Status: UNKNOWN ·Phase: NA

Effect of Liraglutide on Microbiome in Obesity

NCT04046822 ·Status: UNKNOWN ·Phase: PHASE4

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

NCT06171152 ·Status: SUSPENDED ·Phase: EARLY_PHASE1

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

NCT03856047 ·Status: COMPLETED ·Phase: PHASE2

Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity

NCT03523273 ·Status: COMPLETED ·Phase: PHASE2

Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

NCT04186494 ·Status: COMPLETED ·Phase: NA

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

NCT01508949 ·Status: COMPLETED ·Phase: PHASE2

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

NCT02918279 ·Status: COMPLETED ·Phase: PHASE3

Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.

NCT01784965 ·Status: COMPLETED ·Phase: PHASE3

3mg Liraglutide for Overweight or Obesity

NCT03885297 ·Status: COMPLETED

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

NCT03480022 ·Status: COMPLETED ·Phase: PHASE3

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

NCT02963922 ·Status: COMPLETED ·Phase: PHASE3

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

NCT01179048 ·Status: COMPLETED ·Phase: PHASE3

A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers

NCT00978393 ·Status: COMPLETED ·Phase: PHASE1

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06683508 ·Status: COMPLETED ·Phase: PHASE2

The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes

NCT00422058 ·Status: COMPLETED ·Phase: PHASE2

Liraglutide to Improve corONary Haemodynamics During Exercise streSS

NCT02315001 ·Status: COMPLETED ·Phase: PHASE2

Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

NCT04575194 ·Status: UNKNOWN ·Phase: PHASE4

Impact of Liraglutide 3.0 on Body Fat Distribution

NCT03038620 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease

NCT06501326 ·Status: RECRUITING ·Phase: PHASE4